Epidemiological Features of NAFLD From 1999 to 2018 in China
With dramatic changes in lifestyles over the last 20 years, nonalcoholic fatty liver disease (NAFLD) has become the most prevalent liver disorder in China but has not received sufficient attention. NAFLD‐related advanced liver disease and its mortality along with its overall disease burden are expec...
Saved in:
| Published in | Hepatology (Baltimore, Md.) Vol. 71; no. 5; pp. 1851 - 1864 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Wolters Kluwer Health, Inc
01.05.2020
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | With dramatic changes in lifestyles over the last 20 years, nonalcoholic fatty liver disease (NAFLD) has become the most prevalent liver disorder in China but has not received sufficient attention. NAFLD‐related advanced liver disease and its mortality along with its overall disease burden are expected to increase substantially. There is thus an imperative need to clarify the epidemiological features of NAFLD to guide a holistic approach to management. We summarize eight epidemiological features of NAFLD in China over the past two decades using systematic review and meta‐analysis methodology. Our data reveal a rapid growth in the NAFLD population, especially among younger individuals. Importantly, there is a strong ethnic difference in body mass index (BMI) and genetic risk of NAFLD compared with the US population. The etiology of advanced liver disease and its complications (e.g., hepatocellular carcinoma) has been altered because of a Westernized lifestyle and the implementation of effective vaccination strategies against viral hepatitis. Regional epidemiological patterns of NAFLD indicate that economics, environment, and lifestyle are critical factors in disease progression. The analysis also indicates that a large number of patients remain undiagnosed and untreated because of the inadequacy of diagnostic tools and the absence of effective pharmacologic therapies. Given the burden of NAFLD, future policy and research efforts need to address knowledge gaps to mitigate the risk burden. |
|---|---|
| AbstractList | With dramatic changes in lifestyles over the last 20 years, nonalcoholic fatty liver disease (NAFLD) has become the most prevalent liver disorder in China but has not received sufficient attention. NAFLD-related advanced liver disease and its mortality along with its overall disease burden are expected to increase substantially. There is thus an imperative need to clarify the epidemiological features of NAFLD to guide a holistic approach to management. We summarize eight epidemiological features of NAFLD in China over the past two decades using systematic review and meta-analysis methodology. Our data reveal a rapid growth in the NAFLD population, especially among younger individuals. Importantly, there is a strong ethnic difference in body mass index (BMI) and genetic risk of NAFLD compared with the US population. The etiology of advanced liver disease and its complications (e.g., hepatocellular carcinoma) has been altered because of a Westernized lifestyle and the implementation of effective vaccination strategies against viral hepatitis. Regional epidemiological patterns of NAFLD indicate that economics, environment, and lifestyle are critical factors in disease progression. The analysis also indicates that a large number of patients remain undiagnosed and untreated because of the inadequacy of diagnostic tools and the absence of effective pharmacologic therapies. Given the burden of NAFLD, future policy and research efforts need to address knowledge gaps to mitigate the risk burden.With dramatic changes in lifestyles over the last 20 years, nonalcoholic fatty liver disease (NAFLD) has become the most prevalent liver disorder in China but has not received sufficient attention. NAFLD-related advanced liver disease and its mortality along with its overall disease burden are expected to increase substantially. There is thus an imperative need to clarify the epidemiological features of NAFLD to guide a holistic approach to management. We summarize eight epidemiological features of NAFLD in China over the past two decades using systematic review and meta-analysis methodology. Our data reveal a rapid growth in the NAFLD population, especially among younger individuals. Importantly, there is a strong ethnic difference in body mass index (BMI) and genetic risk of NAFLD compared with the US population. The etiology of advanced liver disease and its complications (e.g., hepatocellular carcinoma) has been altered because of a Westernized lifestyle and the implementation of effective vaccination strategies against viral hepatitis. Regional epidemiological patterns of NAFLD indicate that economics, environment, and lifestyle are critical factors in disease progression. The analysis also indicates that a large number of patients remain undiagnosed and untreated because of the inadequacy of diagnostic tools and the absence of effective pharmacologic therapies. Given the burden of NAFLD, future policy and research efforts need to address knowledge gaps to mitigate the risk burden. With dramatic changes in lifestyles over the last 20 years, nonalcoholic fatty liver disease (NAFLD) has become the most prevalent liver disorder in China but has not received sufficient attention. NAFLD‐related advanced liver disease and its mortality along with its overall disease burden are expected to increase substantially. There is thus an imperative need to clarify the epidemiological features of NAFLD to guide a holistic approach to management. We summarize eight epidemiological features of NAFLD in China over the past two decades using systematic review and meta‐analysis methodology. Our data reveal a rapid growth in the NAFLD population, especially among younger individuals. Importantly, there is a strong ethnic difference in body mass index (BMI) and genetic risk of NAFLD compared with the US population. The etiology of advanced liver disease and its complications (e.g., hepatocellular carcinoma) has been altered because of a Westernized lifestyle and the implementation of effective vaccination strategies against viral hepatitis. Regional epidemiological patterns of NAFLD indicate that economics, environment, and lifestyle are critical factors in disease progression. The analysis also indicates that a large number of patients remain undiagnosed and untreated because of the inadequacy of diagnostic tools and the absence of effective pharmacologic therapies. Given the burden of NAFLD, future policy and research efforts need to address knowledge gaps to mitigate the risk burden. With dramatic changes in lifestyles over the last 20 years, nonalcoholic fatty liver disease (NAFLD) has become the most prevalent liver disorder in China but has not received sufficient attention. NAFLD‐related advanced liver disease and its mortality along with its overall disease burden are expected to increase substantially. There is thus an imperative need to clarify the epidemiological features of NAFLD to guide a holistic approach to management. We summarize eight epidemiological features of NAFLD in China over the past two decades using systematic review and meta‐analysis methodology. Our data reveal a rapid growth in the NAFLD population, especially among younger individuals. Importantly, there is a strong ethnic difference in body mass index (BMI) and genetic risk of NAFLD compared with the US population. The etiology of advanced liver disease and its complications (e.g., hepatocellular carcinoma) has been altered because of a Westernized lifestyle and the implementation of effective vaccination strategies against viral hepatitis. Regional epidemiological patterns of NAFLD indicate that economics, environment, and lifestyle are critical factors in disease progression. The analysis also indicates that a large number of patients remain undiagnosed and untreated because of the inadequacy of diagnostic tools and the absence of effective pharmacologic therapies. Given the burden of NAFLD, future policy and research efforts need to address knowledge gaps to mitigate the risk burden. |
| Author | Zhang, Peng Zhou, Feng Cai, Jingjing Ji, Yan‐Xiao Zhou, Jianghua Wang, Wenxin Zhu, Lihua Li, Hongliang She, Zhi‐Gang Zhang, Xiao‐Jing |
| Author_xml | – sequence: 1 givenname: Jianghua surname: Zhou fullname: Zhou, Jianghua organization: Wuhan University – sequence: 2 givenname: Feng surname: Zhou fullname: Zhou, Feng organization: Zhongnan Hospital of Wuhan University – sequence: 3 givenname: Wenxin surname: Wang fullname: Wang, Wenxin organization: Wuhan University – sequence: 4 givenname: Xiao‐Jing surname: Zhang fullname: Zhang, Xiao‐Jing organization: Wuhan University – sequence: 5 givenname: Yan‐Xiao surname: Ji fullname: Ji, Yan‐Xiao organization: Wuhan University – sequence: 6 givenname: Peng surname: Zhang fullname: Zhang, Peng organization: Wuhan University – sequence: 7 givenname: Zhi‐Gang surname: She fullname: She, Zhi‐Gang organization: Wuhan University – sequence: 8 givenname: Lihua surname: Zhu fullname: Zhu, Lihua email: zhulh@whu.edu.cn organization: Wuhan University – sequence: 9 givenname: Jingjing surname: Cai fullname: Cai, Jingjing email: caijingjing83@hotmail.com organization: Central South University – sequence: 10 givenname: Hongliang surname: Li fullname: Li, Hongliang email: zhulh@whu.edu.cn, caijingjing83@hotmail.com, lihl@whu.edu.cn organization: Wuhan University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32012320$$D View this record in MEDLINE/PubMed |
| BookMark | eNp10L1OwzAUBWALgaAUBl4AWWKBIfTazo8tsaDSAlIFDDBbbnIDRklc7ESIt8fQsiBY7OU7R_bZJ9ud65CQIwbnDIBPXnB1LhjLYIuMWMaLRIgMtskIeAGJYkLtkf0QXgFApVzukj3BgfF4jMjFbGUrbK1r3LMtTUPnaPrBY6CupneX88UVnXvXUqaUor2jMSip7ej0xXbmgOzUpgl4uLnH5Gk-e5zeJIv769vp5SIpU6YgkWYpZL3MsRDIZJnXBqEyoLhklZE5YlWITAlcGg4FqCJFLAohZYVVWso0E2Nyuu5defc2YOh1a0OJTWM6dEPQPH5XMch5HunJL_rqBt_F10WlspyluZJRHW_UsGyx0itvW-M_9M8uEUzWoPQuBI-1Lm1veuu63hvbaAb6a3kdl9ffy8fE2a_ET-lfdtP-bhv8-B_qm9nDOvEJ8CaM8A |
| CitedBy_id | crossref_primary_10_1007_s40477_023_00856_7 crossref_primary_10_1155_2021_7692447 crossref_primary_10_1016_j_jep_2024_118468 crossref_primary_10_1016_j_aohep_2022_100726 crossref_primary_10_1186_s12876_020_01334_8 crossref_primary_10_1038_s41598_023_45828_3 crossref_primary_10_1186_s12944_023_01886_0 crossref_primary_10_1038_s41598_023_34462_8 crossref_primary_10_1016_j_numecd_2024_103806 crossref_primary_10_2174_1389557523666230324092842 crossref_primary_10_1186_s12964_023_01292_0 crossref_primary_10_1007_s00011_023_01696_1 crossref_primary_10_1002_hep_31301 crossref_primary_10_1021_acs_est_3c11009 crossref_primary_10_2147_JIR_S490418 crossref_primary_10_3389_fped_2024_1344714 crossref_primary_10_1016_j_aohep_2021_100316 crossref_primary_10_1186_s12967_021_02820_7 crossref_primary_10_1038_s12276_025_01420_5 crossref_primary_10_12677_ACM_2024_142348 crossref_primary_10_1016_j_phrs_2023_106786 crossref_primary_10_12677_acm_2024_143861 crossref_primary_10_1186_s13063_022_06393_8 crossref_primary_10_1136_bmjopen_2020_047588 crossref_primary_10_1016_j_phymed_2024_155478 crossref_primary_10_3389_fgene_2024_1422827 crossref_primary_10_3389_fphar_2024_1437479 crossref_primary_10_1186_s12906_023_03948_3 crossref_primary_10_1016_j_bbrc_2024_149815 crossref_primary_10_12677_ACM_2021_114231 crossref_primary_10_1038_s12276_021_00614_x crossref_primary_10_1016_j_jep_2022_114999 crossref_primary_10_3390_ijms22105375 crossref_primary_10_1002_hep_32774 crossref_primary_10_1111_hex_13665 crossref_primary_10_1016_j_phymed_2024_156317 crossref_primary_10_3724_abbs_2024149 crossref_primary_10_7717_peerj_13022 crossref_primary_10_1053_j_gastro_2023_01_033 crossref_primary_10_1507_endocrj_EJ23_0227 crossref_primary_10_3389_fphys_2023_1272540 crossref_primary_10_3390_ijms22147702 crossref_primary_10_2147_DMSO_S408722 crossref_primary_10_3389_fendo_2024_1464951 crossref_primary_10_1007_s11901_023_00628_1 crossref_primary_10_1016_j_phymed_2024_155337 crossref_primary_10_1016_j_ijbiomac_2021_12_036 crossref_primary_10_1016_j_jcmgh_2021_08_002 crossref_primary_10_1590_1806_9282_20231405 crossref_primary_10_1016_j_envint_2024_108734 crossref_primary_10_3389_fendo_2024_1448359 crossref_primary_10_2147_HMER_S428161 crossref_primary_10_1016_j_jff_2022_104954 crossref_primary_10_1016_j_envpol_2024_124980 crossref_primary_10_3389_fchem_2022_1104249 crossref_primary_10_1016_j_ejim_2023_10_015 crossref_primary_10_1039_D3FO03386D crossref_primary_10_2147_RMHP_S457345 crossref_primary_10_1080_15548627_2023_2254191 crossref_primary_10_3389_fmed_2022_995749 crossref_primary_10_1002_cam4_3045 crossref_primary_10_1093_lifemeta_loac006 crossref_primary_10_1016_j_aohep_2023_101281 crossref_primary_10_1016_j_bcp_2025_116750 crossref_primary_10_1186_s41065_024_00316_0 crossref_primary_10_7717_peerj_14171 crossref_primary_10_3390_biomedicines11092416 crossref_primary_10_2147_DMSO_S438652 crossref_primary_10_1016_j_jhep_2023_03_017 crossref_primary_10_1186_s13098_024_01457_y crossref_primary_10_1080_13813455_2023_2288533 crossref_primary_10_1002_advs_202408660 crossref_primary_10_1016_j_jlr_2023_100382 crossref_primary_10_1080_17435390_2021_1919329 crossref_primary_10_1016_j_livres_2022_09_003 crossref_primary_10_4254_wjh_v16_i3_304 crossref_primary_10_1016_j_dld_2020_09_007 crossref_primary_10_2147_IJGM_S484260 crossref_primary_10_1016_j_jff_2024_106143 crossref_primary_10_1016_j_celrep_2023_112718 crossref_primary_10_3389_fmicb_2025_1517082 crossref_primary_10_1002_cbdv_202400564 crossref_primary_10_1016_j_ijbiomac_2024_138760 crossref_primary_10_1007_s13105_021_00844_7 crossref_primary_10_1016_j_bcp_2024_116594 crossref_primary_10_12677_ACM_2024_142402 crossref_primary_10_1186_s12944_024_02299_3 crossref_primary_10_1016_j_jhep_2023_04_030 crossref_primary_10_1016_j_livres_2021_06_003 crossref_primary_10_3233_THC_231331 crossref_primary_10_7717_peerj_17011 crossref_primary_10_3389_fonc_2022_901705 crossref_primary_10_1016_j_jhepr_2020_100203 crossref_primary_10_3389_fpubh_2021_635818 crossref_primary_10_1016_j_heliyon_2024_e32783 crossref_primary_10_3389_fendo_2023_1078149 crossref_primary_10_1186_s40001_022_00958_8 crossref_primary_10_3389_fphar_2024_1334402 crossref_primary_10_1042_BSR20221375 crossref_primary_10_1007_s13410_023_01255_8 crossref_primary_10_1016_j_mcp_2023_101926 crossref_primary_10_3389_fonc_2024_1442221 crossref_primary_10_1080_07853890_2025_2480250 crossref_primary_10_1186_s12944_023_01988_9 crossref_primary_10_1080_10408398_2021_1939265 crossref_primary_10_1016_j_foodres_2024_114205 crossref_primary_10_1097_HC9_0000000000000639 crossref_primary_10_3389_fgene_2022_931928 crossref_primary_10_1186_s13098_023_01033_w crossref_primary_10_1002_hep_32126 crossref_primary_10_1111_febs_17299 crossref_primary_10_1186_s12944_022_01661_7 crossref_primary_10_3389_fphar_2023_1253715 crossref_primary_10_1038_s42255_023_00896_7 crossref_primary_10_3389_fimmu_2022_967410 crossref_primary_10_1016_j_freeradbiomed_2023_12_017 crossref_primary_10_1016_j_numecd_2024_103799 crossref_primary_10_1039_D4FO01059K crossref_primary_10_1016_j_freeradbiomed_2022_12_095 crossref_primary_10_1186_s12876_025_03759_5 crossref_primary_10_1155_2022_4344905 crossref_primary_10_1038_s41522_023_00399_z crossref_primary_10_1186_s12876_024_03471_w crossref_primary_10_1002_ddr_21991 crossref_primary_10_1016_j_cgh_2022_01_015 crossref_primary_10_1007_s12072_022_10347_2 crossref_primary_10_1002_hep_32139 crossref_primary_10_1016_S1875_5364_21_60002_X crossref_primary_10_1016_j_peptides_2021_170597 crossref_primary_10_1016_j_jep_2023_116950 crossref_primary_10_1172_JCI166149 crossref_primary_10_3389_fnut_2021_745609 crossref_primary_10_1097_j_pbj_0000000000000228 crossref_primary_10_1016_j_jhep_2023_03_040 crossref_primary_10_1002_ame2_12309 crossref_primary_10_1016_j_cmet_2021_09_008 crossref_primary_10_1016_j_heliyon_2024_e33740 crossref_primary_10_1016_j_pharmthera_2023_108428 crossref_primary_10_1016_j_fct_2023_113986 crossref_primary_10_1002_hep_32045 crossref_primary_10_1016_j_jcmgh_2023_08_001 crossref_primary_10_1093_jmcb_mjad060 crossref_primary_10_1155_2022_1254014 crossref_primary_10_1136_egastro_2023_100005 crossref_primary_10_31083_j_rcm2406157 crossref_primary_10_1080_00365521_2022_2032320 crossref_primary_10_1016_j_dld_2023_07_009 crossref_primary_10_3389_fphar_2022_971561 crossref_primary_10_1002_ptr_8347 crossref_primary_10_1016_j_dld_2020_10_034 crossref_primary_10_1042_BSR20211769 crossref_primary_10_1038_s41401_022_00860_3 crossref_primary_10_1080_21655979_2021_2017698 crossref_primary_10_1002_ctm2_1529 crossref_primary_10_1007_s11739_023_03203_0 crossref_primary_10_1002_nbm_5290 crossref_primary_10_1038_s41598_024_84564_0 crossref_primary_10_3389_fnut_2023_1076569 crossref_primary_10_3389_fimmu_2023_1086078 crossref_primary_10_1007_s00420_023_02025_z crossref_primary_10_1016_j_compbiomed_2023_106724 crossref_primary_10_1016_j_obpill_2025_100168 crossref_primary_10_1039_D4MO00060A crossref_primary_10_2196_46891 crossref_primary_10_1152_physiol_00013_2023 crossref_primary_10_3389_fphar_2021_788558 crossref_primary_10_3390_microorganisms11082059 crossref_primary_10_2147_IJN_S452194 crossref_primary_10_3389_fendo_2022_1056283 crossref_primary_10_1016_j_phymed_2024_155398 crossref_primary_10_1016_j_cmet_2021_08_005 crossref_primary_10_3748_wjg_v26_i46_7299 crossref_primary_10_1148_radiol_2021210355 crossref_primary_10_3389_fpubh_2023_1127489 crossref_primary_10_3389_fmed_2025_1509947 crossref_primary_10_1186_s12906_024_04336_1 crossref_primary_10_1016_j_biopha_2021_111255 crossref_primary_10_3390_ijerph19042096 crossref_primary_10_1111_1751_2980_13242 crossref_primary_10_1186_s43042_023_00433_x crossref_primary_10_3389_fendo_2022_864703 crossref_primary_10_3389_fcvm_2023_1119005 crossref_primary_10_4254_wjh_v16_i7_1051 crossref_primary_10_1002_hep_32179 crossref_primary_10_3389_fphar_2024_1360974 crossref_primary_10_1002_hep_32075 crossref_primary_10_1038_s41387_024_00312_3 crossref_primary_10_1002_jsfa_13923 crossref_primary_10_1002_hep_32072 crossref_primary_10_15829_1728_8800_2022_3356 crossref_primary_10_4254_wjh_v16_i4_511 crossref_primary_10_3390_antiox13111389 crossref_primary_10_1007_s11356_023_30306_0 crossref_primary_10_2147_DMSO_S409983 crossref_primary_10_3389_fmolb_2021_824776 crossref_primary_10_5812_hepatmon_145421 crossref_primary_10_3389_fendo_2023_1109673 crossref_primary_10_1186_s12937_024_00968_8 crossref_primary_10_1007_s00261_024_04207_w crossref_primary_10_1161_CIRCRESAHA_121_319059 crossref_primary_10_3389_fendo_2022_1007171 crossref_primary_10_3390_ijerph19116424 crossref_primary_10_7717_peerj_13735 crossref_primary_10_2147_JHC_S439397 crossref_primary_10_12677_ACM_2023_13122772 crossref_primary_10_1208_s12249_022_02255_3 crossref_primary_10_1021_acs_analchem_1c01776 crossref_primary_10_1097_HC9_0000000000000234 crossref_primary_10_1016_j_heliyon_2024_e36193 crossref_primary_10_1007_s00261_024_04448_9 crossref_primary_10_1016_j_canlet_2021_10_039 crossref_primary_10_1097_MEG_0000000000002689 crossref_primary_10_1080_19490976_2024_2351620 crossref_primary_10_1360_SSV_2024_0098 crossref_primary_10_2196_53654 crossref_primary_10_1002_jcp_30934 crossref_primary_10_3389_fnut_2023_1155306 crossref_primary_10_1016_j_bbrc_2024_150003 crossref_primary_10_1089_jmf_2022_K_0052 crossref_primary_10_3390_biomedicines10010005 crossref_primary_10_1016_j_numecd_2023_08_012 crossref_primary_10_3389_fphar_2024_1343755 crossref_primary_10_1097_CM9_0000000000003332 crossref_primary_10_3389_fendo_2023_1241169 crossref_primary_10_1002_mco2_457 crossref_primary_10_1111_1751_2980_13331 crossref_primary_10_3389_fendo_2023_1254459 crossref_primary_10_1177_2042018820969025 crossref_primary_10_1097_HC9_0000000000000343 crossref_primary_10_1016_j_jep_2023_117514 crossref_primary_10_1097_MEG_0000000000002439 crossref_primary_10_1155_2021_6889533 crossref_primary_10_1016_j_jhazmat_2022_128511 crossref_primary_10_1186_s12967_024_05315_3 crossref_primary_10_1038_s41423_020_00560_0 crossref_primary_10_1016_j_puhe_2025_02_028 crossref_primary_10_1016_j_jep_2023_116780 crossref_primary_10_1007_s11101_023_09912_w crossref_primary_10_53469_jcmp_2024_06_12__19 crossref_primary_10_1097_CM9_0000000000001263 crossref_primary_10_3389_fgene_2024_1414835 crossref_primary_10_1016_j_livres_2024_09_003 crossref_primary_10_3390_ijms23052636 crossref_primary_10_55783_rcmf_150205 crossref_primary_10_3390_ijerph18063242 crossref_primary_10_1016_j_lfs_2022_120634 crossref_primary_10_3389_fmicb_2023_1147067 crossref_primary_10_1007_s00330_022_08904_2 crossref_primary_10_1002_fsn3_4176 crossref_primary_10_1111_1753_0407_13430 crossref_primary_10_3390_nu14132749 crossref_primary_10_7555_JBR_37_20230075 crossref_primary_10_3389_fnut_2023_1089909 crossref_primary_10_1016_j_ejphar_2025_177381 crossref_primary_10_1097_HC9_0000000000000046 crossref_primary_10_2188_jea_JE20240224 crossref_primary_10_1016_j_ecoenv_2025_117762 crossref_primary_10_1007_s13187_022_02246_9 crossref_primary_10_3390_biomedicines9101405 crossref_primary_10_1016_j_jhep_2021_05_003 crossref_primary_10_1016_j_metabol_2023_155579 crossref_primary_10_1016_j_phymed_2023_155330 crossref_primary_10_1016_j_scitotenv_2025_179016 crossref_primary_10_3390_jcm11071847 crossref_primary_10_1016_j_livres_2022_05_005 crossref_primary_10_1177_1934578X241306938 crossref_primary_10_1038_s41598_023_47269_4 crossref_primary_10_1186_s12944_024_02129_6 crossref_primary_10_12677_ACM_2022_12111506 crossref_primary_10_1016_j_banm_2024_11_012 crossref_primary_10_1038_s41598_023_43028_7 crossref_primary_10_1186_s12951_022_01456_z crossref_primary_10_1016_j_jhep_2021_11_003 crossref_primary_10_1016_j_ajg_2024_02_003 crossref_primary_10_1016_j_heliyon_2024_e28467 crossref_primary_10_3389_fendo_2023_1210330 crossref_primary_10_1111_eci_13731 crossref_primary_10_3389_fendo_2023_1163682 crossref_primary_10_1186_s40001_024_02032_x crossref_primary_10_1007_s10620_024_08808_9 crossref_primary_10_1111_liv_15812 crossref_primary_10_15829_1728_8800_2025_4316 crossref_primary_10_14218_JCTH_2020_00082 crossref_primary_10_1007_s11739_024_03617_4 crossref_primary_10_1016_j_freeradbiomed_2023_07_026 crossref_primary_10_1016_j_iliver_2023_10_002 crossref_primary_10_36502_2021_ASJBCCR_6237 crossref_primary_10_3389_fmicb_2025_1442282 crossref_primary_10_3390_biomedicines10010083 crossref_primary_10_1007_s12161_024_02718_2 crossref_primary_10_53469_jcmp_2025_07_01__19 crossref_primary_10_1002_hep_31801 crossref_primary_10_1016_j_scitotenv_2023_166831 crossref_primary_10_55783_150205 crossref_primary_10_3390_biomedicines10102530 crossref_primary_10_33667_2782_4101_2022_2_12_16 crossref_primary_10_3748_wjg_v29_i37_5339 crossref_primary_10_1080_14728222_2023_2274099 crossref_primary_10_1016_j_bbrc_2022_07_050 crossref_primary_10_2147_DMSO_S383907 crossref_primary_10_1186_s40001_024_02065_2 crossref_primary_10_1186_s12967_022_03850_5 crossref_primary_10_1186_s13018_024_04717_9 crossref_primary_10_1186_s13098_022_00930_w crossref_primary_10_1007_s00394_023_03179_9 crossref_primary_10_1016_j_lfs_2023_121943 crossref_primary_10_3389_fphar_2021_653641 crossref_primary_10_3389_fnut_2022_964591 crossref_primary_10_7759_cureus_71730 crossref_primary_10_3390_jpm13060945 crossref_primary_10_1039_D1FO02481G crossref_primary_10_1186_s12944_023_01947_4 crossref_primary_10_2147_CLEP_S501445 crossref_primary_10_2196_45943 crossref_primary_10_3389_fphar_2022_1027628 crossref_primary_10_4254_wjh_v14_i4_791 crossref_primary_10_1186_s12944_022_01640_y crossref_primary_10_1016_j_clinre_2022_102056 crossref_primary_10_1016_j_livres_2023_06_001 crossref_primary_10_1016_j_phymed_2023_154961 crossref_primary_10_3390_nu15204375 crossref_primary_10_1016_j_jcte_2024_100341 crossref_primary_10_3724_zdxbyxb_2024_0566 crossref_primary_10_1016_j_dsx_2024_103126 crossref_primary_10_1016_j_phrs_2020_105228 crossref_primary_10_1038_s41598_024_72795_0 crossref_primary_10_1093_gastro_goad032 crossref_primary_10_4081_ejh_2024_4093 crossref_primary_10_5334_gh_1395 crossref_primary_10_3389_fmed_2021_761538 crossref_primary_10_1155_2021_6655335 crossref_primary_10_1016_j_yjmcc_2021_10_007 crossref_primary_10_1016_j_ijbiomac_2024_133969 crossref_primary_10_3390_jcm12082858 crossref_primary_10_1016_j_ypmed_2024_108116 crossref_primary_10_1007_s11427_024_2722_2 crossref_primary_10_1016_j_ijbiomac_2022_08_023 crossref_primary_10_7717_peerj_15860 crossref_primary_10_1016_j_fsi_2023_108803 crossref_primary_10_1111_dom_15014 crossref_primary_10_2147_DMSO_S333431 crossref_primary_10_1186_s12944_021_01568_9 crossref_primary_10_1016_j_ecoenv_2022_113257 crossref_primary_10_1002_hep_31832 crossref_primary_10_1111_dom_15010 crossref_primary_10_1016_j_hbpd_2023_03_009 crossref_primary_10_1016_j_ejim_2020_05_035 crossref_primary_10_3389_fepid_2023_1122790 crossref_primary_10_3389_fgene_2022_1020899 crossref_primary_10_1038_s41401_021_00629_0 crossref_primary_10_3389_fphar_2022_875700 crossref_primary_10_1007_s10863_023_09997_0 crossref_primary_10_1186_s12986_022_00647_7 crossref_primary_10_3389_fped_2022_837116 crossref_primary_10_1186_s12902_022_01172_7 crossref_primary_10_1186_s12951_021_01108_8 crossref_primary_10_1038_s41417_022_00432_x crossref_primary_10_3748_wjg_v27_i1_80 crossref_primary_10_3390_cancers15020551 crossref_primary_10_1007_s13187_024_02404_1 crossref_primary_10_14218_JCTH_2021_00089 crossref_primary_10_1590_1414_431x2024e13229 crossref_primary_10_1016_j_jare_2021_10_004 crossref_primary_10_1016_j_isci_2024_109174 crossref_primary_10_3892_ijmm_2024_5356 crossref_primary_10_3389_fcimb_2022_997018 crossref_primary_10_1007_s00535_023_02040_4 crossref_primary_10_1142_S0192415X24500046 crossref_primary_10_1186_s12889_024_20742_z crossref_primary_10_3389_fgene_2024_1356105 crossref_primary_10_1016_j_cyto_2024_156671 crossref_primary_10_1155_2021_6621644 crossref_primary_10_3390_diseases12120317 crossref_primary_10_3389_fmed_2023_1294267 crossref_primary_10_1111_eci_13768 crossref_primary_10_1016_j_jpsychires_2023_03_041 crossref_primary_10_1093_lifemeta_loac034 crossref_primary_10_3389_fnut_2024_1447524 crossref_primary_10_1016_j_phrs_2023_106925 crossref_primary_10_1002_hep_31852 crossref_primary_10_1159_000536447 crossref_primary_10_1111_eci_13597 crossref_primary_10_3389_fcvm_2022_891963 crossref_primary_10_1002_mco2_70130 crossref_primary_10_3390_ijerph20021426 crossref_primary_10_1126_scitranslmed_ade7347 crossref_primary_10_1016_j_ejrad_2024_111709 crossref_primary_10_2147_JIR_S468093 crossref_primary_10_1038_s41423_020_00579_3 crossref_primary_10_1080_03602532_2023_2202359 crossref_primary_10_1002_hep_31749 crossref_primary_10_1016_j_metabol_2021_154874 crossref_primary_10_1016_j_freeradbiomed_2025_03_021 crossref_primary_10_1016_j_heliyon_2023_e18321 crossref_primary_10_1177_00033197241227501 crossref_primary_10_3390_ijms242417508 crossref_primary_10_1002_hep4_1948 crossref_primary_10_2147_DMSO_S332659 crossref_primary_10_1038_s41598_024_74841_3 crossref_primary_10_3390_ijms26052253 crossref_primary_10_1097_MEG_0000000000002807 crossref_primary_10_1111_1751_2980_12967 crossref_primary_10_1155_2021_4853355 crossref_primary_10_1055_a_1862_9088 crossref_primary_10_3389_fphar_2023_1194026 crossref_primary_10_2147_NDT_S375532 crossref_primary_10_1097_MCG_0000000000002055 crossref_primary_10_1097_MD_0000000000031980 crossref_primary_10_1186_s13018_023_04168_8 crossref_primary_10_1016_j_intimp_2024_112821 crossref_primary_10_1016_j_phymed_2024_155712 crossref_primary_10_1016_j_bj_2025_100838 crossref_primary_10_1016_j_freeradbiomed_2022_07_024 crossref_primary_10_1016_j_phymed_2023_154661 crossref_primary_10_1096_fj_202401464R crossref_primary_10_1016_j_fct_2021_111978 crossref_primary_10_1016_j_biopha_2023_114319 crossref_primary_10_1016_j_heliyon_2024_e29860 crossref_primary_10_1002_hep_31881 crossref_primary_10_1080_07853890_2023_2255825 crossref_primary_10_1021_acs_jnatprod_2c00259 crossref_primary_10_1038_s41598_024_83013_2 crossref_primary_10_1155_2021_6642246 crossref_primary_10_1007_s12072_022_10395_8 crossref_primary_10_1038_s41430_023_01326_3 crossref_primary_10_1039_D2FO02774G crossref_primary_10_1021_acs_jafc_3c06498 crossref_primary_10_1038_s41598_022_17511_6 crossref_primary_10_1186_s12876_024_03302_y crossref_primary_10_1186_s12889_025_21943_w crossref_primary_10_2147_DMSO_S469677 crossref_primary_10_1111_jcmm_17042 crossref_primary_10_3350_cmh_2024_0431 crossref_primary_10_3390_diagnostics12061412 crossref_primary_10_1016_j_apsb_2022_05_001 crossref_primary_10_3389_fendo_2023_1161402 crossref_primary_10_1016_j_cyto_2023_156459 |
| Cites_doi | 10.1016/j.jhep.2014.12.012 10.6061/clinics/2015(08)06 10.1016/j.jnutbio.2010.10.002 10.1111/obr.12407 10.1016/j.jhep.2015.11.004 10.1016/j.cgh.2018.05.059 10.1016/j.amepre.2017.06.008 10.1002/hep.30702 10.1016/j.jhep.2017.06.003 10.1016/j.jhep.2017.09.021 10.1007/s10620-018-5389-5 10.1002/hep.29721 10.3748/wjg.v22.i30.6890 10.1002/hep4.1018 10.1146/annurev-med-090514-013832 10.1016/j.clinre.2018.03.014 10.1053/j.gastro.2019.02.002 10.3748/wjg.v20.i47.17932 10.1002/hep.29367 10.1016/j.ijid.2011.10.009 10.3748/wjg.v22.i32.7236 10.1007/s00125-011-2446-4 10.1007/s11606-019-05340-9 10.1111/jgh.13856 10.1056/NEJMra1503519 10.1002/hep.28785 10.1016/j.jhep.2017.10.015 10.1002/med.21515 10.3727/105221619X15536120524171 10.1002/hep.28431 10.1016/j.cgh.2018.05.057 10.3748/wjg.v20.i37.13546 10.1016/S2468-1253(19)30039-1 10.1111/j.1445-5994.2012.02848.x 10.1002/hep.27406 10.1111/j.1440-1746.2009.05914.x |
| ContentType | Journal Article |
| Copyright | 2020 by the American Association for the Study of Liver Diseases. |
| Copyright_xml | – notice: 2020 by the American Association for the Study of Liver Diseases. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7TM 7TO 7U9 H94 K9. 7X8 |
| DOI | 10.1002/hep.31150 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Nucleic Acids Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic AIDS and Cancer Research Abstracts MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1527-3350 |
| EndPage | 1864 |
| ExternalDocumentID | 32012320 10_1002_hep_31150 HEP31150 |
| Genre | reviewArticle Research Support, Non-U.S. Gov't Journal Article Review |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GrantInformation_xml | – fundername: The Key Project Of The National Natural Science Foundation funderid: 81630011 – fundername: The Creative Group Project Of Hubei Province funderid: 2016cfa010 – fundername: The Hubei Science And Technology Support Project funderid: 2018bec473 – fundername: The National Science Foundation Of China funderid: 81570271; 81570412 – fundername: The National Science Foundation Of China funderid: 81870171 – fundername: The National Key R&D Program Of China funderid: 2016yff0101504 – fundername: The National Science Fund For Distinguished Young Scholars funderid: 81425005 – fundername: The Major Research Plan Of The National Natural Science Foundation Of China funderid: 91639304; 91729303 – fundername: The Hunan Distinguished Young Scholars funderid: 2017rs3015 |
| GroupedDBID | --- --K .3N .55 .GA .GJ .Y3 05W 0R~ 10A 186 1B1 1CY 1L6 1OB 1OC 1ZS 1~5 24P 31~ 33P 3O- 3SF 3WU 4.4 4G. 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 7-5 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEDT AAESR AAEVG AAHHS AALRI AANHP AAONW AAQFI AAQQT AAQXK AASGY AAXRX AAXUO AAZKR ABCQN ABCUV ABEML ABIJN ABLJU ABMAC ABOCM ABPVW ABWVN ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACLDA ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADMUD ADNMO ADOZA ADXAS ADZMN ADZOD AECAP AEEZP AEIMD AENEX AEQDE AEUQT AFBPY AFFNX AFGKR AFPWT AFUWQ AFZJQ AHMBA AIACR AIURR AIWBW AJAOE AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD F00 F01 F04 F5P FD8 FDB FEDTE FGOYB FUBAC G-S G.N GNP GODZA H.X HBH HF~ HHY HHZ HVGLF HZ~ IHE IX1 J0M J5H JPC KBYEO KQQ LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M41 M65 MJL MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ NNB NQ- O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K R2- RGB RIG RIWAO RJQFR ROL RPZ RWI RX1 RYL SEW SSZ SUPJJ TEORI UB1 V2E V9Y W2D W8V W99 WBKPD WH7 WHWMO WIB WIH WIJ WIK WIN WJL WOHZO WQJ WRC WUP WVDHM WXI X7M XG1 XV2 ZGI ZXP ZZTAW ~IA ~WT AAYXX ABJNI ACZKN AFNMH AGQPQ AHQVU CITATION MEWTI WXSBR AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EIF NPM 7T5 7TM 7TO 7U9 ADSXY H94 K9. 7X8 |
| ID | FETCH-LOGICAL-c4190-8ab38fb6e73e18c6fae0da09281da86eed73593eba2070974ee77388ded4c8453 |
| IEDL.DBID | DR2 |
| ISSN | 0270-9139 1527-3350 |
| IngestDate | Thu Jul 10 23:56:56 EDT 2025 Wed Aug 13 10:51:19 EDT 2025 Mon Jul 21 06:05:05 EDT 2025 Thu Apr 24 23:07:11 EDT 2025 Tue Jul 01 03:33:57 EDT 2025 Wed Jan 22 16:35:00 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| License | 2020 by the American Association for the Study of Liver Diseases. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4190-8ab38fb6e73e18c6fae0da09281da86eed73593eba2070974ee77388ded4c8453 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| PMID | 32012320 |
| PQID | 2395614698 |
| PQPubID | 996352 |
| PageCount | 6 |
| ParticipantIDs | proquest_miscellaneous_2350910626 proquest_journals_2395614698 pubmed_primary_32012320 crossref_citationtrail_10_1002_hep_31150 crossref_primary_10_1002_hep_31150 wiley_primary_10_1002_hep_31150_HEP31150 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | May 2020 |
| PublicationDateYYYYMMDD | 2020-05-01 |
| PublicationDate_xml | – month: 05 year: 2020 text: May 2020 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | Hepatology (Baltimore, Md.) |
| PublicationTitleAlternate | Hepatology |
| PublicationYear | 2020 |
| Publisher | Wolters Kluwer Health, Inc |
| Publisher_xml | – name: Wolters Kluwer Health, Inc |
| References | 2019; 9 2009; 24 2019; 4 2017; 1 2019; 70 2013; 28 2019; 72 2015; 70 2013; 43 2019; 34 2017; 67 2019; 39 2019; 17 2019; 19 2012; 16 2018; 67 2016; 17 2017; 377 2014; 60 2012; 55 2018; 42 2018; 68 2014; 20 2018; 6 2017; 53 2019; 64 2015; 62 2019; 69 2016; 64 2019 2011; 22 2018; 33 2019; 156 2016; 67 2016; 22 (hep31150-bib-0014-20241017) 2019; 17 (hep31150-bib-0015-20241017) 2016; 67 (hep31150-bib-0008-20241017) 2017; 67 (hep31150-bib-0036-20241017) 2017; 1 (hep31150-bib-0026-20241017) 2019 (hep31150-bib-0024-20241017) 2019; 64 (hep31150-bib-0018-20241017) 2017; 377 (hep31150-bib-0022-20241017) 2019; 156 (hep31150-bib-0006-20241017) 2019; 70 (hep31150-bib-0003-20241017) 2019; 4 (hep31150-bib-0005-20241017) 2019; 9 (hep31150-bib-0004-20241017) 2014; 60 (hep31150-bib-0011-20241017) 2018; 33 (hep31150-bib-0001-20241017) 2018; 68 (hep31150-bib-0039-20241017) 2013; 43 (hep31150-bib-0028-20241017) 2018; 68 (hep31150-bib-0012-20241017) 2016; 64 (hep31150-bib-0013-20241017) 2018; 6 (hep31150-bib-0019-20241017) 2016; 64 (hep31150-bib-0020-20241017) 2016; 17 (hep31150-bib-0021-20241017) 2012; 16 (hep31150-bib-0002-20241017) 2019; 39 (hep31150-bib-0023-20241017) 2009; 24 (hep31150-bib-0030-20241017) 2016; 22 (hep31150-bib-0007-20241017) 2017; 53 (hep31150-bib-0025-20241017) 2019; 34 (hep31150-bib-0035-20241017) 2014; 20 (hep31150-bib-0042-20241017) 2018; 68 (hep31150-bib-0016-20241017) 2015; 70 (hep31150-bib-0029-20241017) 2019; 17 (hep31150-bib-0031-20241017) 2016; 22 (hep31150-bib-0033-20241017) 2016; 64 (hep31150-bib-0038-20241017) 2015; 62 (hep31150-bib-0017-20241017) 2014; 20 (hep31150-bib-0037-20241017) 2018; 42 (hep31150-bib-0040-20241017) 2013; 28 (hep31150-bib-0034-20241017) 2011; 22 (hep31150-bib-0032-20241017) 2012; 55 (hep31150-bib-0027-20241017) 2019; 72 (hep31150-bib-0010-20241017) 2018; 67 (hep31150-bib-0009-20241017) 2019; 69 (hep31150-bib-0041-20241017) 2019; 19 |
| References_xml | – volume: 156 start-page: 2230 year: 2019 end-page: 2241 article-title: Incidence and etiology of drug‐induced liver injury in mainland China publication-title: Gastroenterology – volume: 24 start-page: 1786 year: 2009 end-page: 1790 article-title: Non‐alcoholic fatty liver disease: an expanding problem with low levels of awareness in Hong Kong publication-title: J Gastroenterol Hepatol – year: 2019 article-title: Awareness of nonalcoholic fatty liver disease is increasing but remains very low in a representative US cohort publication-title: Dig Dis Sci – volume: 4 start-page: 389 year: 2019 end-page: 398 article-title: Prevalence, incidence, and outcome of non‐alcoholic fatty liver disease in Asia, 1999‐2019: a systematic review and meta‐analysis publication-title: Lancet Gastroenterol Hepatol – volume: 28 start-page: 81 issue: Suppl 4 year: 2013 end-page: 87 article-title: Role of diet and nutritional management in non‐alcoholic fatty liver disease publication-title: J Gastroenterol Hepatol – volume: 70 start-page: 1119 year: 2019 end-page: 1133 article-title: Unexpected rapid increase in the burden of nonalcoholic fatty liver disease in China from 2008 to 2018: a systematic review and meta‐analysis publication-title: Hepatology – volume: 69 start-page: 564 year: 2019 end-page: 568 article-title: Epidemiology of chronic liver diseases in the USA in the past three decades publication-title: Gut – volume: 33 start-page: 86 year: 2018 end-page: 98 article-title: The Asia‐Pacific working party on non‐alcoholic fatty liver disease guidelines 2017‐Part 2: management and special groups publication-title: J Gastroenterol Hepatol – volume: 64 start-page: 708 year: 2019 end-page: 717 article-title: Awareness and knowledge of nonalcoholic fatty liver disease among office employees in Beijing publication-title: China. Dig Dis Sci – volume: 22 start-page: 6890 year: 2016 end-page: 6905 article-title: Herbal medicines and nonalcoholic fatty liver disease publication-title: World J Gastroenterol – volume: 17 start-page: 748 year: 2019 end-page: 755.e3 article-title: Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates publication-title: Clin Gastroenterol Hepatol – volume: 43 start-page: 247 year: 2013 end-page: 253 article-title: Awareness and opinions of non‐alcoholic fatty liver disease by hospital specialists publication-title: Intern Med J – volume: 68 start-page: 362 year: 2018 end-page: 375 article-title: Pharmacotherapy for NASH: current and emerging publication-title: J Hepatol – volume: 22 start-page: 699 year: 2011 end-page: 711 article-title: Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms publication-title: J Nutr Biochem – volume: 1 start-page: 53 year: 2017 end-page: 60 article-title: Nonalcoholic fatty liver disease‐related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma publication-title: Hepatol Commun – volume: 62 start-page: S47 year: 2015 end-page: S64 article-title: NAFLD: a multisystem disease publication-title: J Hepatol – volume: 53 start-page: 567 year: 2017 end-page: 575 article-title: Prevalence and trends in lifetime obesity in the U.S., 1988–2014 publication-title: Am J Prev Med – volume: 64 start-page: 1577 year: 2016 end-page: 1586 article-title: The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe publication-title: Hepatology – volume: 20 start-page: 13546 year: 2014 end-page: 13555 article-title: Study of liver cirrhosis over ten consecutive years in Southern China publication-title: World J Gastroenterol – volume: 67 start-page: 328 year: 2018 end-page: 357 article-title: The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases publication-title: Hepatology – volume: 17 start-page: 630 year: 2019 end-page: 637.e8 article-title: Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants publication-title: Clin Gastroenterol Hepatol – volume: 68 start-page: 335 year: 2018 end-page: 352 article-title: Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? publication-title: J Hepatol – volume: 19 start-page: 175 year: 2019 end-page: 185 article-title: Current and emerging approaches for nonalcoholic steatohepatitis treatment publication-title: Gene Expr – volume: 67 start-page: 862 year: 2017 end-page: 873 article-title: New trends on obesity and NAFLD in Asia publication-title: J Hepatol – volume: 72 start-page: 14 year: 2019 end-page: 24 article-title: A cross‐sectional study of the public health response to non‐alcoholic fatty liver disease in Europe publication-title: J Hepatol – volume: 55 start-page: 885 year: 2012 end-page: 904 article-title: Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non‐alcoholic fatty liver disease (NAFLD): a systematic review and meta‐analysis of randomised trials publication-title: Diabetologia – volume: 9 year: 2019 article-title: Disease burden of liver cancer in China from 1997 to 2016: an observational study based on the Global Burden of Diseases publication-title: BMJ Open – volume: 68 start-page: 349 year: 2018 end-page: 360 article-title: Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis publication-title: Hepatology – volume: 17 start-page: 510 year: 2016 end-page: 519 article-title: Obesity is an independent risk factor for non‐alcoholic fatty liver disease: evidence from a meta‐analysis of 21 cohort studies publication-title: Obes Rev – volume: 67 start-page: 103 year: 2016 end-page: 117 article-title: Liver cancer: connections with obesity, fatty liver, and cirrhosis publication-title: Annu Rev Med – volume: 22 start-page: 7236 year: 2016 end-page: 7251 article-title: Transient elastography (FibroScan((R))) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease—where do we stand? publication-title: World J Gastroenterol – volume: 6 start-page: 420 year: 2018 end-page: 424 article-title: Nonalcoholic fatty liver disease: epidemiology, liver transplantation trends and outcomes, and risk of recurrent disease in the graft publication-title: J Clin Transl Hepatol – volume: 39 start-page: 328 year: 2019 end-page: 348 article-title: Progress and challenges in the prevention and control of nonalcoholic fatty liver disease publication-title: Med Res Rev – volume: 64 start-page: 73 year: 2016 end-page: 84 article-title: Global epidemiology of nonalcoholic fatty liver disease‐meta‐analytic assessment of prevalence, incidence, and outcomes publication-title: Hepatology – volume: 60 start-page: 2099 year: 2014 end-page: 2108 article-title: The global burden of liver disease: the major impact of China publication-title: Hepatology – volume: 377 start-page: 2063 year: 2017 end-page: 2072 article-title: Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis publication-title: N Engl J Med – volume: 16 start-page: e82 year: 2012 end-page: e88 article-title: Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20‐year period publication-title: Int J Infect Dis – volume: 34 start-page: 2772 year: 2019 end-page: 2778 article-title: Awareness of nonalcoholic fatty liver disease in a population‐based cohort sample: the CARDIA study publication-title: J Gen Intern Med – volume: 42 start-page: 443 year: 2018 end-page: 452 article-title: A changing etiologic scenario in liver transplantation for hepatocellular carcinoma in a multicenter cohort study from Latin America publication-title: Clin Res Hepatol Gastroenterol – volume: 70 start-page: 563 year: 2015 end-page: 568 article-title: Non‐alcoholic steatohepatitis‐related liver cirrhosis is increasing in China: a ten‐year retrospective study publication-title: Clinics (Sao Paulo) – volume: 64 start-page: 1388 year: 2016 end-page: 1402 article-title: EASL‐EASD‐EASO clinical practice guidelines for the management of non‐alcoholic fatty liver disease publication-title: J Hepatol – volume: 20 start-page: 17932 year: 2014 end-page: 17940 article-title: Lean‐non‐alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population publication-title: World J Gastroenterol – volume: 62 start-page: S47 year: 2015 ident: hep31150-bib-0038-20241017 article-title: NAFLD: a multisystem disease publication-title: J Hepatol doi: 10.1016/j.jhep.2014.12.012 – volume: 70 start-page: 563 year: 2015 ident: hep31150-bib-0016-20241017 article-title: Non‐alcoholic steatohepatitis‐related liver cirrhosis is increasing in China: a ten‐year retrospective study publication-title: Clinics (Sao Paulo) doi: 10.6061/clinics/2015(08)06 – volume: 22 start-page: 699 year: 2011 ident: hep31150-bib-0034-20241017 article-title: Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms publication-title: J Nutr Biochem doi: 10.1016/j.jnutbio.2010.10.002 – volume: 17 start-page: 510 year: 2016 ident: hep31150-bib-0020-20241017 article-title: Obesity is an independent risk factor for non‐alcoholic fatty liver disease: evidence from a meta‐analysis of 21 cohort studies publication-title: Obes Rev doi: 10.1111/obr.12407 – year: 2019 ident: hep31150-bib-0026-20241017 article-title: Awareness of nonalcoholic fatty liver disease is increasing but remains very low in a representative US cohort publication-title: Dig Dis Sci – volume: 64 start-page: 1388 year: 2016 ident: hep31150-bib-0012-20241017 article-title: EASL‐EASD‐EASO clinical practice guidelines for the management of non‐alcoholic fatty liver disease publication-title: J Hepatol doi: 10.1016/j.jhep.2015.11.004 – volume: 17 start-page: 630 year: 2019 ident: hep31150-bib-0029-20241017 article-title: Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2018.05.059 – volume: 9 year: 2019 ident: hep31150-bib-0005-20241017 article-title: Disease burden of liver cancer in China from 1997 to 2016: an observational study based on the Global Burden of Diseases publication-title: BMJ Open – volume: 53 start-page: 567 year: 2017 ident: hep31150-bib-0007-20241017 article-title: Prevalence and trends in lifetime obesity in the U.S., 1988–2014 publication-title: Am J Prev Med doi: 10.1016/j.amepre.2017.06.008 – volume: 70 start-page: 1119 year: 2019 ident: hep31150-bib-0006-20241017 article-title: Unexpected rapid increase in the burden of nonalcoholic fatty liver disease in China from 2008 to 2018: a systematic review and meta‐analysis publication-title: Hepatology doi: 10.1002/hep.30702 – volume: 67 start-page: 862 year: 2017 ident: hep31150-bib-0008-20241017 article-title: New trends on obesity and NAFLD in Asia publication-title: J Hepatol doi: 10.1016/j.jhep.2017.06.003 – volume: 68 start-page: 335 year: 2018 ident: hep31150-bib-0001-20241017 article-title: Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? publication-title: J Hepatol doi: 10.1016/j.jhep.2017.09.021 – volume: 64 start-page: 708 year: 2019 ident: hep31150-bib-0024-20241017 article-title: Awareness and knowledge of nonalcoholic fatty liver disease among office employees in Beijing publication-title: China. Dig Dis Sci doi: 10.1007/s10620-018-5389-5 – volume: 68 start-page: 349 year: 2018 ident: hep31150-bib-0028-20241017 article-title: Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis publication-title: Hepatology doi: 10.1002/hep.29721 – volume: 22 start-page: 6890 year: 2016 ident: hep31150-bib-0031-20241017 article-title: Herbal medicines and nonalcoholic fatty liver disease publication-title: World J Gastroenterol doi: 10.3748/wjg.v22.i30.6890 – volume: 1 start-page: 53 year: 2017 ident: hep31150-bib-0036-20241017 article-title: Nonalcoholic fatty liver disease‐related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma publication-title: Hepatol Commun doi: 10.1002/hep4.1018 – volume: 67 start-page: 103 year: 2016 ident: hep31150-bib-0015-20241017 article-title: Liver cancer: connections with obesity, fatty liver, and cirrhosis publication-title: Annu Rev Med doi: 10.1146/annurev-med-090514-013832 – volume: 42 start-page: 443 year: 2018 ident: hep31150-bib-0037-20241017 article-title: A changing etiologic scenario in liver transplantation for hepatocellular carcinoma in a multicenter cohort study from Latin America publication-title: Clin Res Hepatol Gastroenterol doi: 10.1016/j.clinre.2018.03.014 – volume: 156 start-page: 2230 year: 2019 ident: hep31150-bib-0022-20241017 article-title: Incidence and etiology of drug‐induced liver injury in mainland China publication-title: Gastroenterology doi: 10.1053/j.gastro.2019.02.002 – volume: 72 start-page: 14 year: 2019 ident: hep31150-bib-0027-20241017 article-title: A cross‐sectional study of the public health response to non‐alcoholic fatty liver disease in Europe publication-title: J Hepatol – volume: 20 start-page: 17932 year: 2014 ident: hep31150-bib-0035-20241017 article-title: Lean‐non‐alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population publication-title: World J Gastroenterol doi: 10.3748/wjg.v20.i47.17932 – volume: 67 start-page: 328 year: 2018 ident: hep31150-bib-0010-20241017 article-title: The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases publication-title: Hepatology doi: 10.1002/hep.29367 – volume: 16 start-page: e82 year: 2012 ident: hep31150-bib-0021-20241017 article-title: Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20‐year period publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2011.10.009 – volume: 22 start-page: 7236 year: 2016 ident: hep31150-bib-0030-20241017 article-title: Transient elastography (FibroScan((R))) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease—where do we stand? publication-title: World J Gastroenterol doi: 10.3748/wjg.v22.i32.7236 – volume: 55 start-page: 885 year: 2012 ident: hep31150-bib-0032-20241017 article-title: Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non‐alcoholic fatty liver disease (NAFLD): a systematic review and meta‐analysis of randomised trials publication-title: Diabetologia doi: 10.1007/s00125-011-2446-4 – volume: 34 start-page: 2772 year: 2019 ident: hep31150-bib-0025-20241017 article-title: Awareness of nonalcoholic fatty liver disease in a population‐based cohort sample: the CARDIA study publication-title: J Gen Intern Med doi: 10.1007/s11606-019-05340-9 – volume: 33 start-page: 86 year: 2018 ident: hep31150-bib-0011-20241017 article-title: The Asia‐Pacific working party on non‐alcoholic fatty liver disease guidelines 2017‐Part 2: management and special groups publication-title: J Gastroenterol Hepatol doi: 10.1111/jgh.13856 – volume: 377 start-page: 2063 year: 2017 ident: hep31150-bib-0018-20241017 article-title: Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis publication-title: N Engl J Med doi: 10.1056/NEJMra1503519 – volume: 64 start-page: 1577 year: 2016 ident: hep31150-bib-0019-20241017 article-title: The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe publication-title: Hepatology doi: 10.1002/hep.28785 – volume: 68 start-page: 362 year: 2018 ident: hep31150-bib-0042-20241017 article-title: Pharmacotherapy for NASH: current and emerging publication-title: J Hepatol doi: 10.1016/j.jhep.2017.10.015 – volume: 39 start-page: 328 year: 2019 ident: hep31150-bib-0002-20241017 article-title: Progress and challenges in the prevention and control of nonalcoholic fatty liver disease publication-title: Med Res Rev doi: 10.1002/med.21515 – volume: 6 start-page: 420 year: 2018 ident: hep31150-bib-0013-20241017 article-title: Nonalcoholic fatty liver disease: epidemiology, liver transplantation trends and outcomes, and risk of recurrent disease in the graft publication-title: J Clin Transl Hepatol – volume: 28 start-page: 81 issue: Suppl 4 year: 2013 ident: hep31150-bib-0040-20241017 article-title: Role of diet and nutritional management in non‐alcoholic fatty liver disease publication-title: J Gastroenterol Hepatol – volume: 19 start-page: 175 year: 2019 ident: hep31150-bib-0041-20241017 article-title: Current and emerging approaches for nonalcoholic steatohepatitis treatment publication-title: Gene Expr doi: 10.3727/105221619X15536120524171 – volume: 69 start-page: 564 year: 2019 ident: hep31150-bib-0009-20241017 article-title: Epidemiology of chronic liver diseases in the USA in the past three decades publication-title: Gut – volume: 64 start-page: 73 year: 2016 ident: hep31150-bib-0033-20241017 article-title: Global epidemiology of nonalcoholic fatty liver disease‐meta‐analytic assessment of prevalence, incidence, and outcomes publication-title: Hepatology doi: 10.1002/hep.28431 – volume: 17 start-page: 748 year: 2019 ident: hep31150-bib-0014-20241017 article-title: Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2018.05.057 – volume: 20 start-page: 13546 year: 2014 ident: hep31150-bib-0017-20241017 article-title: Study of liver cirrhosis over ten consecutive years in Southern China publication-title: World J Gastroenterol doi: 10.3748/wjg.v20.i37.13546 – volume: 4 start-page: 389 year: 2019 ident: hep31150-bib-0003-20241017 article-title: Prevalence, incidence, and outcome of non‐alcoholic fatty liver disease in Asia, 1999‐2019: a systematic review and meta‐analysis publication-title: Lancet Gastroenterol Hepatol doi: 10.1016/S2468-1253(19)30039-1 – volume: 43 start-page: 247 year: 2013 ident: hep31150-bib-0039-20241017 article-title: Awareness and opinions of non‐alcoholic fatty liver disease by hospital specialists publication-title: Intern Med J doi: 10.1111/j.1445-5994.2012.02848.x – volume: 60 start-page: 2099 year: 2014 ident: hep31150-bib-0004-20241017 article-title: The global burden of liver disease: the major impact of China publication-title: Hepatology doi: 10.1002/hep.27406 – volume: 24 start-page: 1786 year: 2009 ident: hep31150-bib-0023-20241017 article-title: Non‐alcoholic fatty liver disease: an expanding problem with low levels of awareness in Hong Kong publication-title: J Gastroenterol Hepatol doi: 10.1111/j.1440-1746.2009.05914.x |
| SSID | ssj0009428 |
| Score | 2.7031097 |
| SecondaryResourceType | review_article |
| Snippet | With dramatic changes in lifestyles over the last 20 years, nonalcoholic fatty liver disease (NAFLD) has become the most prevalent liver disorder in China but... With dramatic changes in lifestyles over the last 20 years, nonalcoholic fatty liver disease (NAFLD) has become the most prevalent liver disorder in China but... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1851 |
| SubjectTerms | Body Mass Index China - epidemiology Cost of Illness Epidemiology Etiology Fatty liver Hepatitis Hepatocellular carcinoma Hepatology Holistic Health Humans Life Style Liver cancer Liver diseases Non-alcoholic Fatty Liver Disease - diagnosis Non-alcoholic Fatty Liver Disease - epidemiology Non-alcoholic Fatty Liver Disease - therapy Prevalence Risk Factors Vaccination |
| Title | Epidemiological Features of NAFLD From 1999 to 2018 in China |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhep.31150 https://www.ncbi.nlm.nih.gov/pubmed/32012320 https://www.proquest.com/docview/2395614698 https://www.proquest.com/docview/2350910626 |
| Volume | 71 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEB4WD-LF92N9EcWDl2pt-kQvolsW0UXEBQ9CSdIsitrKbvfir3cmfSzrA8RbodMmzSSZ72uSbwAOsNdIl4vUoniOBMW1rdDX2vIj5XlKBp6fml2-Pb_bd68evIcWnNZnYUp9iOaHG40MM1_TABdydDwRDX3SSNhPSr5Oe7UIEN1NpKMi1-RVRdZl0-pyVKsK2c5x8-R0LPoGMKfxqgk48QI81lUt95m8HI0LeaQ-vqg4_vNbFmG-AqLsvOw5S9DS2TLM3lRL7Stw1pnkjiVHMgKLYyTnLB-w3nl8fcniYf7GSGCAFTnDEB-y54yZhNyr0I879xddq0q1YCnXHCYXkocD6euA65NQ-QOh7VTYkYNwVpDz0oB7EddSODhHIAfROgh4GKY6dVXoenwNZrI80xvAJAIGESidOoFA7o1vF8oNfMR5A41o0G7DYd3oiap0yCkdxmtSKig7CbZGYlqjDfuN6XspvvGT0XbtuaQaf6PE4XRgl7JjtmGvuY0jh5ZDRKbzMdkYsISMrg3rpcebUrhjsCZV1vjt9-KTbufWXGz-3XQL5hyi7Wbf5DbMFMOx3kFsU8hd04k_AcJT7mU |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1JS8NAFH5IBfXivsR1FA9eUmMmK3gR21K1FhELvUiYTKYoaiLaXvz1vjdZSl1AvAUyySTz5s37vlm-B3CIvSZ2uEhMiudIUBzLDDylTC-Uritj3_USvcu367V7zmXf7U_BaXkWJteHqCbcyDP0eE0OThPSx2PV0AeFjP1EE_ZpyuhNyvmN27F4VOjozKrIuyxaXw5LXSHLPq4enYxG3yDmJGLVIae1APflx-Y7TZ7qo2Fclx9fdBz_-zeLMF9gUXaWd54lmFLpMsxcF6vtK3DaHKePJVsywosj5OcsG7DuWavTYK237IWRxgAbZgyjfMAeU6Zzcq9Cr9W8O2-bRbYFUzr6PLmIeTCIPeVzdRJIbyCUlQgrtBHRCrJf4nM35CoWNg4TSEOU8n0eBIlKHBk4Ll-DWpqlagNYjJhB-FIlti-QfuPbhXR8D6HeQCEgtAw4Kls9koUUOWXEeI5yEWU7wtaIdGsYcFAVfc31N34qtF2aLipc8D2yOZ3ZpQSZBuxXt9F5aEVEpCobURmNl5DUGbCem7yqhdsabtLHasP9Xn3Ubt7oi82_F92D2fbddSfqXHSvtmDOJhavt1FuQ234NlI7CHWG8a7u0Z-9s_KB |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS8MwFD4MBfHF-2U6NYoPvlRrk97Ql-FWps4h4mAPQknTFEVtZW4v_npP0suYFxDfCk2bNCcn5_ua5DsAhzhqIkZ5bKh4jgSFmYbnSGk4vrBtEbm2E-tdvj2n02dXA3tQg7PyLEyuD1H9cFOeoedr5eBvcXIyEQ19lEjYTzVfn2WO6au8Da27iXaUz3RiVaRdplpe9ktZIdM6qR6dDkbfEOY0YNURJ1iEh7Kt-UaT5-PxKDoWH19kHP_5MUuwUCBR0syHzjLUZLoCczfFWvsqnLcnyWOVJYlCi2Nk5yRLSK8ZdFskGGavRCkMkFFGMMZ75CklOiP3GvSD9v1FxyhyLRiC6dPkPKJeEjnSpfLUE07CpRlz07cQz3Jlvdiltk9lxC2cJJCESOm61PNiGTPhMZuuw0yapXITSISIgbtCxpbLkXzj27lgroNAL5EIB806HJWdHopCiFzlw3gJcwllK8TeCHVv1OGgKvqWq2_8VKhRWi4sHPA9tKg6savSY9Zhv7qNrqPWQ3gqs7Eqo9ESUro6bOQWr2qhlgabqrHabr9XH3bat_pi6-9F92DuthWE3cve9TbMW4rC6z2UDZgZDcdyB3HOKNrV4_kT5mnxMA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Epidemiological+Features+of+NAFLD+From+1999+to+2018+in+China&rft.jtitle=Hepatology+%28Baltimore%2C+Md.%29&rft.au=Zhou%2C+Jianghua&rft.au=Zhou%2C+Feng&rft.au=Wang%2C+Wenxin&rft.au=Xiao%E2%80%90Jing+Zhang&rft.date=2020-05-01&rft.pub=Wolters+Kluwer+Health%2C+Inc&rft.issn=0270-9139&rft.eissn=1527-3350&rft.volume=71&rft.issue=5&rft.spage=1851&rft.epage=1864&rft_id=info:doi/10.1002%2Fhep.31150&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-9139&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-9139&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-9139&client=summon |